One-of-a-kind non-injection nasal spray is now FDA-sanctioned for anaphylaxis

The FDA-approved Epinephrine nasal spray for type I allergic reactions, including potentially fatal anaphylaxis in emergencies, was mentioned in its press release on 9th August 2024. This innovative product is approved for use in individuals who weigh around 66 pounds or more, both adults and children. It signifies a significant progress in managing allergic emergencies. Anaphylaxis is a grave, rapid-onset allergic reaction that may impact many body parts. Certain foods, medicines, and insect bites are common triggers, with symptoms varying from hives and swelling to trouble breathing and loss of consciousness.

Historically, epinephrine—the only life-saving anaphylaxis therapy—has been administered via injection. The approval of this nasal spray has been backed by extensive research. Four studies involving 175 healthy individuals demonstrated that this nasal spray supplies epinephrine into the bloodstream at comparable levels to the standard injections. It also showed comparable results on blood pressure and heart rate—key indicators of the treatment's efficacy. Trials in the pediatric population over 66 pounds established that the spray's effectiveness is consistent across age groups.

This nasal spray is designed for single-use administration into one nostril, with the choice of a second dose if symptoms continue or deteriorate. Patients should seek emergency medical care if needed. The spray comes with caution for those with certain nasal conditions or coexisting health issues, and common side effects include throat irritation, nasal discomfort, and headache. This nasal spray has been given Fast Track designation by the FDA, reflecting its potential to address a substantial unmet medical need.